The cost-effectiveness of high-dose oral proton pump inhibition after endoscopy in the acute treatment of peptic ulcer bleeding

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 2, 2004, Pages 195-202

  Barkun, A N ^a,b   Herba, K ^a   Adam, V ^a,b   Kennedy, W ^c   Fallone, C A ^a   Bardou, M ^a,d  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PANTOPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR;

ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG EFFICACY; GASTROINTESTINAL ENDOSCOPY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; PEPTIC ULCER BLEEDING; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

COST-BENEFIT ANALYSIS; ENDOSCOPY, GASTROINTESTINAL; HUMANS; LENGTH OF STAY; MODELS, ECONOMIC; PEPTIC ULCER HEMORRHAGE; PROTON PUMPS; RANDOMIZED CONTROLLED TRIALS;

EID: 3242881122     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02035.x     Document Type: Article

References (55)

1. Blatchford O, Davidson LA, Murray WR, Blatchford M, Pell J. Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study. BMJ 1997; 315: 510-4.
2. Longstreth GF, Feitelberg SP. Outpatient care of selected patients with acute non-variceal upper gastrointestinal haemorrhage. Lancet 1995; 345: 108-11.
3. Gralnek IM, Jensen DM, Gornbein J, et al. Clinical and economic outcomes of individuals with severe peptic ulcer hemorrhage and nonbleeding visible vessel: an analysis of two prospective clinical trials. Am J Gastroenterol 1998; 93: 2047-56.
4. Gralnek M, Jensen DM, Kovacs TO, et al. An economic analysis of patients with active arterial peptic ulcer hemorrhage treated with endoscopic heater probe, injection sclerosis, or surgery in a prospective, randomized trial. Gastrointest Endosc 1997; 46: 105-12.
5. Lee JG, Turnipseed S, Romano PS, et al. Endoscopy-based triage significantly reduces hospitalization rates and costs of treating upper GI bleeding: a randomized controlled trial. Gastrointest Endosc 1999; 50: 755-61.
6. Jiranek GC, Kozarek RA, A cost-effective approach to the patient with peptic ulcer bleeding. Surg Clin N Am 1996; 76: 83-103.
7. Kong SX, Hatoum HT, Zhao SZ, Agrawal NM, Geis SG. Prevalence and cost of hospitalization for gastrointestinal complications related to peptic ulcers with bleeding or perforation: comparison of two national databases. Am J Manag Care 1998; 4: 399-409.
8. Quirk DM, Barry MJ, Aserkoff B, Podolsky DK. Physician specialty and variations in the cost of treating patients with acute upper gastrointestinal bleeding. Gastroenterology 1997; 113: 1443-8.
9. Jensen DM. Endoscopic control of non-variceal upper gastrointestinal hemorrhage. In: Yamada, T, Alpers, DH, Laine, L, Owyang, C, Powell, DW, eds. Textbook of Gastroenterology. 3rd edn. Philadelphia: Lipincott Williams & Wilkins, 1999: 2857-79.
10. Nationwide Inpatient Sample (NIS). http://www.ahrq.gov/ data/hcup/hcupnis.htm. Accessed: May 26, 2003.
11. Barkun AN, Herba K, Adam V, Kennedy W, Fallone CA, Bardou M. High-dose intravenous proton pump inhibition following endoscopic therapy in the acute management of patients with bleeding peptic ulcers in the USA and Canada: a cost-effectiveness analysis. Aliment Pharmacol Ther 2004; 19: 591-600.
12. Spiegel BM, Ofman JJ, Woods K, Vakil NB. Minimizing recurrent peptic ulcer hemorrhage after endoscopic hemostasis: the cost-effectiveness of competing strategies. Am J Gastroenterol 2003; 98: 86-97.
13. Wyeth Pharmaceuticals. http://www.wyeth.com/index.asp. Accessed: May 26, 2003.
14. Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Non-Varical Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic Hemostasis and Proton Pump Inhibition are associated with Improved Outcomes in a Reat-Life Setting. Am J Gastroenterol 2004: in press.
15. Lin HJ, Lo WC, Lee FY, Perng CL, Tseng GY. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med 1998; 158: 54-8.
16. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000; 343: 310-6.
17. Hasselgren G, Lind T, Lundell L, et al. Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study. Scand J Gastroenterol 1997; 32: 328-33.
18. Schaffalitzky de Muckadell OB, Havelund T, Harling H, et al. Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study. Scand J Gastroenterol 1997; 32: 320-7.
19. Udd M, Miettinen P, Palmu A, et al. Regular-dose versus high-dose omeprazole in peptic ulcer bleeding: a prospective randomized double-blind study. Scand J Gastroenterol 2001; 36: 1332-8.
20. Barkun AN, Cockeram AW, Plourde V, Fedorak RN. Review article: acid suppression in non-variceal acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 1999; 13: 1565-84.
21. Bustamante M, Stollman N. The efficacy of proton-pump inhibitors in acute ulcer bleeding: a qualitative review. J Clin Gastroenterol 2000; 30: 7-13.
22. Yacyshyn BR, Thomson AB. Critical review of acid suppression in nonvariceal, acute, upper gastrointestinal bleeding. Dig Dis 2000; 18: 117-28.
23. Erstad BL. Proton-pump inhibitors for acute peptic ulcer bleeding. Ann Pharmacother 2001; 35: 730-40.
24. Gisbert JP, Gonzalez L, Calvet X, Roque M, Gabriel R, Pajares JM. Proton pump inhibitors versus H2-antagonists: a metaanalysis of their efficacy in treating bleeding peptic ulcer. Aliment Pharmacol Ther 2001; 15: 917-26.
25. Zed PJ, Loewen PS, Slavik RS, Marra CA. Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers. Ann Pharmacother 2001; 35: 1528-34.
26. Huggins RM, Scates AC, Latour JK. Intravenous proton-pump inhibitors versus H(2)-antagonists for treatment of GI bleeding. Ann Pharmacother 2003; 37: 433-7.
27. Elta GH. Acute nonvariceal upper gastrointestinal hemorrhage. Curr Treat Options Gastroenterol 2002; 5: 147-52.
28. Metz DC. Potential uses of intravenous proton pump inhibitors to control gastric acid secretion. Digestion 2000; 62: 73-81.
29. Selby NM, Kubba AK, Hawkey CJ. Acid suppression in peptic ulcer haemorrhage: a 'meta-analysis'. Aliment Pharmacol Ther 2000; 14: 1119-26.
30. Michel P, Duhamel C, Bazin B, et al. Lansoprazole versus ranitidine in the prevention of early recurrences of digestive hemorrhages from gastroduodenal ulcers. Randomized double-blind multicenter study. Gastroenterol Clin Biol 1994; 18: 1102-5.
31. Coraggio F, Rotondano G, Marmo R, et al. Somatostatin in the prevention of recurrent bleeding after endoscopic haemostasis of peptic ulcer haemorrhage: a preliminary report. Eur J Gastroenterol Hepatol 1998; 10: 673-6.
32. Fasseas P, Leybishkis B, Rocca G. Omeprazole versus ranitidine in the medical treatment of acute upper gastrointestinal bleeding: assessment by early repeat endoscopy. Int J Clin Pract 2001; 55: 661-4.
33. Khuroo MS, Yattoo GN, Javid G, et al. A comparison of omeprazole and placebo for bleeding peptic ulcer. N Engl J Med 1997; 336: 1054-8.
34. Javid G, Masoodi I, Zargar SA, et al. Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer. Am J Med 2001; 111: 280-4.
35. Jung HK, Son HY, Jung SA, et al. Comparison of oral omeprazole and endoscopic ethanol injection therapy for prevention of recurrent bleeding from peptic ulcers with nonbleeding visible vessels or fresh adherent clots. Am J Gastroenterol 2002; 97: 1736-40.
36. Kaviani MJ, Hashemi MR, Kazemifar AR, et al. Effect of oral omeprazole in reducing re-bleeding in bleeding peptic ulcers: a prospective, double-blind, randomized, clinical trial. Aliment Pharmacol Ther 2003; 17: 211-6.
37. Green FW Jr, Kaplan MM, Curtis LE, Levine PH. Effect of acid and pepsin on blood coagulation and platelet aggregation. A possible contributor prolonged gastroduodenal mucosal hemorrhage. Gastroenterology 1978; 74: 38-43.
38. Li Y, Sha W, Nie Y, et al. Effect of intragastric pH on control of peptic ulcer bleeding. J Gastroenterol Hepatol 2000; 15: 148-54.
39. Chaimoff C, Creter D, Djaldetti M. The effect of pH on platelet and coagulation factor activities. Am J Surg 1978; 136: 257-9.
40. Berstad A. Does profound acid inhibition improve haemostasis in peptic ulcer bleeding? Scand J Gastroenterol 1997; 32: 396-8.
41. Berstad A, Holm H, Kittang E. Experience with antipeptic agents. Scand J Gastroenterol 1979; 14(Suppl. 55): 121-3.
42. Vreeburg EM, Levi M, Rauws EA, et al. Enhanced mucosal fibrinolytic activity in gastroduodenal ulcer haemorrhage and the beneficial effect of acid suppression. Aliment Pharmacol Ther 2001; 15: 639-46.
43. Walt RP, Cottrell J, Mann SG, Freemantle NP, Langman MJ. Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 1992; 340: 1058-62.
44. Levine JE, Leontiadis GI, Sharma VK, Howden CW. Metaanalysis: the efficacy of intravenous H2-receptor antagonists in bleeding peptic ulcer. Aliment Pharmacol Ther 2002; 16: 1137-42.
45. Collins R, Langman M. Treatment with histamine H2 antagonists in acute upper gastrointestinal hemorrhage. Implications of randomized trials. N Engl J Med 1985; 313: 660-6.
46. Daneshmend TK, Hawkey CJ, Langman MJ, Logan RF, Long RG, Walt RP. Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. BMJ 1992; 304: 143-7.
47. Bardou M, Toubouti Y, Benhaberou-Brun D, Rahme E, Barkun A. High-dose proton pump inhibition decrease both re-bleeding and mortality in high-risk patients with acute peptic ulcer bleeding. A series of meta-analyses. Gastroenterology 2003; 1234(Suppl. 1): A625.
48. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-55.
49. Barkun A, Bardou M, Marshall JK. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding. Ann Intern Med 2003; 139: 843-57.
50. Lee KK, You JH, Wong IC, et al. Cost-effectiveness analysis of high-dose omeprazole infusion as adjuvant therapy to endoscopic treatment of bleeding peptic ulcer. Gastrointest Endosc 2003; 57: 160-4.
51. Herba K, Kennedy W, Barkun AN. Cost-effectiveness of IV PPI's in the treatment of non-variceal upper GI bleeding following urgent endoscopy. Can J Gastroenterol 2002; 16(Suppl. A): 87A.
52. Rich M, Scheiman JM, Tierney W, Fendrick AM. Is upper gastrointestinal radiography a cost-effective alternative to a Helicobacter pylori "test and treat" strategy for patients with suspected peptic ulcer disease? Am J Gastroenterol 2000; 95: 651-8.
53. Gagnon YM, Levy AR, Eloubeidi MA, Arguedas MR, Rioux KP, Enns RA. Cost implications of administering intravenous proton pump inhibitors to all patients presenting to the emergency department with peptic ulcer bleeding. Value Health 2003; 6: 457-65.
54. Enns RA, Gagnon YM, Rioux KP, Levy AR. Cost-effectiveness in Canada of intravenous proton pump inhibitors for all patients presenting with acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 2003; 17: 225-33.
55. Marshall JK, Collins SM, Gafni A. Demographic predictors of resource utilization for bleeding peptic ulcer disease: the Ontario GI Bleed Study. J Clin Gastroenterol 1999; 29: 165-70.